Newsroom

Sorted by: Latest

-

Smurfit Westrock to Announce 2026 Third Quarter Results on October 28, 2026

DUBLIN--(BUSINESS WIRE)--Smurfit Westrock plc (NYSE:SW) plans to release its financial results for the third quarter ended September 30, 2026 on Wednesday, October 28, 2026 at 6:30 am ET (10:30 am GMT). Smurfit Westrock’s earnings release and related materials will be available at smurfitwestrock.com At 7:30 am ET (11:30 am GMT) on the same day, Smurfit Westrock’s senior management team will host a webcast for analysts and institutional investors. The webcast will be available at https://invest...
-

Walker & Dunlop Closes $151 Million Through HUD’s New LEAN Express Lane

BETHESDA, Md.--(BUSINESS WIRE)--Walker & Dunlop has arranged $151 million in financing across nine healthcare transactions nationwide through the (HUD) LEAN Express Lane....
-

Used EVs May Be More Reliable Than You Think. VinFast Is Making Them Easier to Buy

MARKHAM, Ontario--(BUSINESS WIRE)--Electric vehicles have been on the road for more than two decades, giving researchers an increasingly substantial body of real-world data to assess how they hold up over time. And the findings may surprise some drivers: studies suggest that as vehicles accumulate mileage, the simpler mechanical architecture of EVs can work increasingly in their favor. It makes sense when you think about it. Unlike gasoline-powered vehicles, EVs do not require a conventional en...
-

Wabtec Reports Strong Third Quarter 2026 Results, Raised and Tightened Adjusted EPS Guidance

PITTSBURGH--(BUSINESS WIRE)--Wabtec Corporation (NYSE: WAB) today reported third quarter 2026 GAAP earnings per diluted share of $2.42, up 33.7% versus the third quarter of 2025. Adjusted earnings per diluted share were $2.83, up 22.0% versus the same quarter a year ago. Third quarter sales were $3.12 billion and cash from operations was $455 million. “Wabtec delivered another strong quarter, evidenced by sales growth, margin expansion and a 22% increase in adjusted EPS,” said Rafael Santana, W...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 20.10.2026 FEX.LN IE00B8X9NW27 1,372,712.00 USD 156,061,061.33  113.688  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 20.10.2026 MISL.LN IE000NVDQXE1 4,425,002.00 USD 141,927,158.59   32.074  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 20.10.2026 CHPS.LN IE000KXTLDE2  775,002.00 USD  35,346,789.44   45.609  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 20.10.2026 QSEP.LN IE000FQ808R5  550,002.00 USD  13,868,563.35   25.215  ...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Virta Health Reports 37% Greater Weight Loss When GLP-1s are Paired with its AI-enabled Personalized Nutrition

DENVER--(BUSINESS WIRE)--Virta Health, the leader in metabolic disease reversal, today released its 2026 Reversal Report: Metabolic Care in the GLP-1 Era with a striking finding: Virta members taking GLP-1s achieved substantially better results when medication was paired with the company’s AI-enabled, clinically supervised, personalized nutrition therapy. In a real-world analysis of more than 4,000 adults, those who followed the Virta Method™ achieved 37% greater weight loss after one year than...